Mitophagy in cardiovascular diseases: molecular mechanisms, pathogenesis, and treatment

Amir Ajoolabady1, Mario Chiong2, Sergio Lavandero3

  • 1Shanghai Institute of Cardiovascular Diseases, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Insights

Cardiovascular disease (CVD) impacts mitochondrial health. This review explores mitophagy

Area of Science:

  • Cardiovascular Disease Research
  • Mitochondrial Biology
  • Cellular Mechanisms

Background:

  • Cardiovascular disease (CVD) is a growing global health concern.
  • Mitochondrial injury is a key factor in CVD development.
  • Mitochondrial dynamics and mitophagy are crucial for cardiomyocyte health.

Purpose of the Study:

  • To review the dual role of mitophagy in cardiovascular disease (CVD) pathogenesis.
  • To summarize current controversies and recent findings in mitophagy research.
  • To identify compounds that can modulate mitophagy for potential therapeutic applications.

Main Methods:

  • Literature review of scientific articles on mitophagy and CVD.
  • Analysis of the mechanisms underlying mitophagy dysregulation in CVD.
  • Identification and summary of novel compounds targeting mitophagy.

Main Results:

  • Mitophagy plays a complex, dual role in CVD, influencing both protective and detrimental pathways.
  • Dysregulation of mitophagy homeostasis contributes to mitochondrial damage and cardiomyocyte death in CVD.
  • Several compounds have been identified that modulate mitophagy, offering potential therapeutic avenues.

Conclusions:

  • Understanding the intricate role of mitophagy in CVD is crucial for developing new treatments.
  • Further research is needed to elucidate the precise mechanisms of mitophagy dysregulation.
  • Targeting mitophagy pathways holds promise for novel therapeutic strategies against CVD.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
31
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31